Publication date: Sep 01, 2019
Perivascular epitheliod cell tumors (PEComas) are rare mesenchymal neoplasms for which the role of systemic treatments is not established as there are no published prospective clinical trials or sufficiently large retrospective case series. The aim of this study is to clarify the activity of conventional chemotherapy and biological agents in advanced/metastatic PEComas.
This was an observational, retrospective, international study that included patients with advanced/metastatic PEComa treated with systemic therapy at 5 European sarcoma reference centers and within the Italian Rare Cancer Network. Survival analyses were performed using the Kaplan-Meier method and the Cox hazards regression models.
A total of 53 patients were included. Cytotoxic chemotherapy regimens were active only in a small proportion of PEComas. Gemcitabine-based regimens [objective response rate (ORR): 20%, median progression-free survival (PFS): 3.4 months] seemed to have the same activity of anthracycline-based regimens (ORR: 13%, median PFS: 3.2 months). Antiangiogenic agents resulted in disease stabilization in some patients, with a number having density changes/tissue response on imaging, with an ORR of 8.3% and a median PFS of 5.4 months. mTOR inhibitors were the most active agents, with an ORR of 41% and a median PFS of 9 months.
Our study provides data for the selection of systemic therapy in patients with advanced/metastatic PEComa: mTOR inhibitors are the most active agents. Antiangiogenics and chemotherapy with gemcitabine-based regimens or anthracycline-based regimens are options in further line, but with a lower response rate and PFS.
Sanfilippo, R., Jones, R.L., Blay, J.Y., Le Cesne, A., Provenzano, S., Antoniou, G., Mir, O., Fuc`a, G., Fumagalli, E., Bertulli, R., Stacchiotti, S., Brahmi, M., Grosso, F., Dufresne, A., Hindi, N., Sbaraglia, M., Gronchi, A., Collini, P., Dei Tos, A.P., and Casali, P.G. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). 24043. 2019 Clin Cancer Res (25):17.
|disease||MESH||Perivascular Epithelioid Cell Tumors|
- Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.
- New paradigm for stage III melanoma: from surgery to adjuvant treatment.
- Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.